Latest Insider Transactions at Precision Biosciences Inc (DTIL)
This section provides a real-time view of insider transactions for Precision Biosciences Inc (DTIL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PRECISION BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PRECISION BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.12%
|
$0
$0.04 P/Share
|
|
Feb 18
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,871
-0.17%
|
$82,452
$12.2 P/Share
|
|
Feb 18
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.54%
|
$0
$0.04 P/Share
|
|
Feb 17
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,705
-0.51%
|
$116,460
$12.28 P/Share
|
|
Feb 17
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.13%
|
$0
$0.04 P/Share
|
|
Feb 16
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,697
-0.52%
|
$126,061
$13.3 P/Share
|
|
Feb 16
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.13%
|
$0
$0.04 P/Share
|
|
Jan 29
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,444
-0.16%
|
$77,328
$12.25 P/Share
|
|
Jan 29
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,515
+0.55%
|
$0
$0.04 P/Share
|
|
Jan 28
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,444
-0.17%
|
$70,884
$11.97 P/Share
|
|
Jan 28
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.55%
|
$0
$0.04 P/Share
|
|
Jan 27
2021
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,048
-0.18%
|
$77,528
$11.68 P/Share
|
|
Jan 27
2021
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+0.55%
|
$0
$0.04 P/Share
|
|
Jan 26
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,697
-0.52%
|
$126,061
$13.37 P/Share
|
|
Jan 26
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,515
+1.14%
|
$0
$0.04 P/Share
|
|
Jan 25
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
9,695
-0.52%
|
$126,035
$13.74 P/Share
|
|
Jan 25
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.15%
|
$0
$0.04 P/Share
|
|
Jan 22
2021
|
Matthew R. Kane President and CEO |
SELL
Open market or private sale
|
Direct |
10,218
-0.56%
|
$132,834
$13.53 P/Share
|
|
Jan 22
2021
|
Matthew R. Kane President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,514
+1.16%
|
$0
$0.04 P/Share
|
|
Jan 21
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.39%
|
$160,000
$16.49 P/Share
|
|
Aug 31
2020
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
3,156
+37.64%
|
$12,624
$4.79 P/Share
|
|
Feb 28
2020
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,072
+50.0%
|
$10,360
$5.61 P/Share
|